Resultado de búsqueda
7 de may. de 2024 · Lovo-cel was approved as Lyfgenia in December 2023. The first patient with sickle cell disease (SCD) is set to receive bluebird bio’s lovotibeglogene autotemcel (lovo-cel) after completing a cell collection at Children’s National Hospital in Washington. 1,2 Lovo-cel was approved as Lyfgenia by the FDA in December 2023. 3.
6 de may. de 2024 · SOMERVILLE, Mass., May 06, 2024--bluebird bio, Inc. (Nasdaq: BLUE) announced today that it has completed the first commercial cell collection for LYFGENIA (lovotibeglogene autotemcel), a one-time gene therapy for the treatment of sickle cell disease in patients with a history of vaso-occlusive events. LYFGENIA was approved by the FDA in December 2023 and is the most deeply studied gene therapy ...
6 de may. de 2024 · Published 05/06/2024, 03:12 PM. 0. BLUE. -0.29%. SOMERVILLE, Mass. - bluebird bio, Inc. (NASDAQ:BLUE) has achieved a significant milestone with the first commercial cell collection for its FDA ...
7 de may. de 2024 · Bluebird set Lyfgenia’s price at $3.1 million, while Vertex Pharmaceuticals, which developed Casgevy with CRISPR Therapeutics, is charging $2.2 million for its treatment. The high cost has raised concerns about patient access as well as impact on the budget of Medicaid, which covers many of the 20,000 or so people in the U.S. estimated to have sickle cell.
9 de may. de 2024 · commercial gene therapy team well-positioned to lead in hemoglobinopathies. Significant commercial head start . leveraging ZYNTEGLO launch synergies – same treating physicians, same QTCs, same payers. 1. 3. Recognized gene therapy leader with deep gene therapy expertise, manufacturing experience and commercial infrastructure
7 de may. de 2024 · Bluebird, for its part, boasts around 60 U.S. treatment centers for its gene therapies, Mizuho’s Syed pointed out. Related Vertex jumps to TreeFrog to enhance production of Type 1 diabetes cell ...
Hace 6 días · The gene-editing treatment, called Exa-cel and using the brand name Casgevy, was jointly developed by Vertex Pharmaceuticals of Boston and CRISPR Therapeutics of Switzerland. It is the first treatment to be approved that uses CRISPR, the Nobel Prize-winning gene editing tool, to snip patients' DNA. The other treatment, called Lyfgenia and made ...
